Zafgen (ZFGN) Reports Q2 Loss of $2.96

Zafgen (NASDAQ: ZFGN) reported Q2 EPS of ($2.96), versus ($4.37) reported last year.

2014 Financial Guidance

The Company expects to end 2014 with greater than $95 million in cash and cash equivalents.

"Zafgen is pleased to have completed its IPO in June 2014 and with the $102.7 million in net proceeds from the offering expects to end 2014 with greater than $95 million in cash and cash equivalents," said Patricia Allen, Chief Financial Officer of Zafgen. "We believe this financial position enables us to build our business, including executing on the three clinical trials we will be conducting in 2014 and 2015."

For earnings history and earnings-related data on Zafgen (ZFGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c